Evotec Stock Buoyed By Takeda Alliance

Evotec and Takeda aim to develop at least five drug candidates by leveraging the German group’s discovery platform.

Test_Tube
Evotec entered a multi-year drug discovery pact with Takeda. • Source: Shutterstock

Evotec SE received a share price boost on 24 September after the German biotech announced its latest multi-year drug discovery collaboration, this time with Japan-based with Takeda Pharmaceutical Co. Ltd., under which the duo will aim to develop at least five drug candidates by leveraging Evotec's drug discovery platform.

Their therapeutic focus will be on oncology, gastroenterology, neuroscience and rare diseases.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip